高级检索
当前位置: 首页 > 详情页

Association between comorbidities and extraglandular manifestations in primary Sjögren’s syndrome: a multicenter cross-sectional study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Rheumatology, Peking Union Medical CollegeHospital, Peking Union Medical College and Chinese Academy ofMedical Sciences, National Clinical Research Center forImmunologic Diseases, Ministry of Science & Technology, KeyLaboratory of Rheumatology and Clinical Immunology, Ministry ofEducation, No. 1 Shuaifuyuan, Beijing 100730, China [2]Department of Rheumatology, Shanxi Bethune Hospital,Taiyuan, China [3]Department of Rheumatology, The First People’s Hospital ofYunnanProvince, Kunming, China [4]Department of Rheumatology and Immunology, The First AffiliatedHospital, China Medical University, Shenyang, China [5]Department of Rheumatology and Immunology, The SecondHospital of Dalian Medical University, Dalian, China [6]Department of Rheumatology, The Second Affiliated Hospital ofNanchang University, Nanchang, China [7]Department of Rheumatology, Jiangsu Provincial People’s Hospital,Nanjing, China [8]Department of Rheumatology, The First Affiliated Hospital of USTC(Anhui Provincial Hospital), Hefei, China [9]Department of Rheumatology, The First Affiliated Hospital ofBaotou Medical College, Baotou, China [10]Department of Rheumatology, The First Affiliated Hospital ofKunming Medical University, Kunming, China [11]Department of Epidemiology and Biostatistics, Institute of BasicMedical Sciences Chinese Academy ofMedical Sciences, School ofBasic Medicine Peking Union Medical College, Beijing, China [12]Section of Rheumatology, Allergy and Immunology, Department ofInternalMedicine, Yale School ofMedicine, New Haven, CT, USA
出处:
ISSN:

关键词: Comorbidity Extraglandular manifestation Sjögren’s syndrome

摘要:
Introduction: Primary Sjögren’s syndrome (pSS) has been related to a higher risk of comorbidities, but studies examining comorbidities among patients with and without extraglandular manifestations are limited. The objectives of this study were to assess the prevalence of comorbidities in Chinese pSS patients and to determine the relationship between comorbidities and extraglandular manifestations. Method: This cross-sectional study was based on the multicenter pSS registry established by the Chinese Rheumatism Data Center. Patients fulfilling the 2002 American-European criteria or the 2016 classification criteria for pSS were enrolled from May 2016 to December 2018. Demographic data, disease characteristics, comorbidities (cardiovascular disease, thyroid disorder, malignancy, and fragility fracture), and extraglandular manifestations were collected. Multivariate analyses were used to assess the relationships between comorbidities and extraglandular manifestations. Results: A total of 4087 pSS patients were included (95.7% female and mean age of 51.2 ± 13.1 years). The baseline prevalence of comorbidities was 3.8% for cardiovascular diseases, 12.1% for thyroid disorders, 1.8% for malignancies, and 1.7% for fragility fractures. The presence of extraglandular manifestations was associated with more comorbidities. Patients with more than one extraglandular manifestation had a higher prevalence of cardiovascular disease (adjusted odds ratio [aOR] 2.004, 95% confidence interval [CI] 1.221–3.288), thyroid disorder (aOR 1.380, 95% CI 1.022–1.863), and fragility fracture (aOR 2.684, 95% CI 1.505–4.786) after adjustment for age, sex, disease duration, and the significant variables in the univariate analysis. Conclusions: The presence of extraglandular manifestations in pSS was associated with an increased comorbidity burden, especially cardiovascular disease, thyroid disorder, and fragility fracture.Key Points• This is the first study assessing the association between extraglandular manifestations and comorbidity burden based on the largest pSS registry in China.• Patients with multiple extraglandular manifestations tend to have increased comorbid cardiovascular disease, thyroid disorder, and fragility fracture. © 2020, International League of Associations for Rheumatology (ILAR).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 风湿病学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 风湿病学
JCR分区:
出版当年[2019]版:
Q3 RHEUMATOLOGY
最新[2023]版:
Q2 RHEUMATOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of Rheumatology, Peking Union Medical CollegeHospital, Peking Union Medical College and Chinese Academy ofMedical Sciences, National Clinical Research Center forImmunologic Diseases, Ministry of Science & Technology, KeyLaboratory of Rheumatology and Clinical Immunology, Ministry ofEducation, No. 1 Shuaifuyuan, Beijing 100730, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82494 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号